GPCR structure-based virtual screening approach for CB2 antagonist search

Area of Science:

• Pharmacology and Drug Discovery
• Computational Chemistry
• Structural Biology

Background:

• Cannabinoid (CB) receptors are crucial G-protein-coupled receptor (GPCR) targets for therapeutic intervention.
• Lack of experimental 3D structures for CB receptors hinders drug design.
• Homology models can introduce inaccuracies in virtual screening.

Purpose of the Study:

• To establish a structure-based virtual screening protocol for identifying CB2 bioactive antagonists.
• To develop and validate a method for examining homology-predicted CB2 receptor models and binding pockets.
• To create a reliable in silico strategy for discovering novel CB2 antagonist leads.

Main Methods:

• Generated a 3D CB2 receptor homology model and refined it using molecular dynamics (MD/MM) calculations.
• Employed flexible docking and FlexX-Pharm docking against a known antagonist database for validation.
• Developed a 3D testing database query algorithm and a consensus scoring (CScore) function.

Main Results:

• The refined 3D CB2 model and binding pocket were validated against known antagonists.
• The virtual screening protocol successfully distinguished known antagonists from random molecules.
• The CScore function effectively ranked ligand-receptor binding interactions.

Conclusions:

• The developed structure-based virtual screening approach is a viable strategy for identifying novel CB2 antagonist leads.
• This method overcomes limitations of existing homology models for in silico drug design.
• The protocol offers a new pathway for therapeutic specificity in regulating diseases via CB receptors.